ID
45866
Descrizione
Principal Investigator: Richard Wilson, McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA MeSH: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001005 This study of three metastatic melanoma patients utilized exome sequencing and RNA sequencing to help identify putative neoantigen peptides that could be further validated by standard immunological assays before design of a personalized vaccine. For each set of neoantigens identified and verified by standard assays, we designed GMP peptides that correspond to the top neoantigens, then used these to condition dendritic cell isolates from each patient. The conditioned dendritic cells were used as the vaccine in three rounds of vaccination, followed by monitoring for T cell memory response to each of the neoantigens.
collegamento
Keywords
versioni (1)
- 14/10/23 14/10/23 - Simon Heim
Titolare del copyright
Richard Wilson, McDonnell Genome Institute, Washington University School of Medicine, St. Louis, MO, USA
Caricato su
14 ottobre 2023
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
dbGaP phs001005 Antigen Discovery in Melanoma
Subject ID, consent group, and affection status of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID and gender of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Sample ID, histological type, analyte type, body site where sample was obtained, tumor status of sample, and year when sample was collected from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
Similar models
Subject ID, consent group, and affection status of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- StudyEvent: SEV1
- Subject ID, consent group, and affection status of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID, sample ID, and sample use variable obtained from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Subject ID and gender of participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
- Sample ID, histological type, analyte type, body site where sample was obtained, tumor status of sample, and year when sample was collected from participants with melanoma and involved in the "Identification of Putative Neoantigens in Stage III Melanoma" project.
C2348585 (UMLS CUI [1,2])
C0035168 (UMLS CUI [1,2])
C0556660 (UMLS CUI [1,3])
C0011900 (UMLS CUI [1,2])